Immunotherapy Drug Tarlatamab Approved for Advanced Small Cell Lung Cancer
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
Progress Against Cancer
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a new imaging modality to predict glioblastoma response, and more.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.
Researchers at the AACR Annual Meeting 2024 examined new treatment options for brain tumors.
Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Researchers are exploring new options for kidney cancer treatments.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More